Corona Virus Infection, Covid19, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Pneumonia, COVID-19 Respiratory Infection, Mass Screening, Vaccine Virus Shedding
Conditions
Keywords
infrasound, ultrasound, vibroacoustics, vibrome, digital-biosignature, e-stethoscope
Brief summary
This study generates robust, uniform clinical data across emerging COVID-19 strains to train ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for digital diagnostic feature synthesis of asymptomatic and symptomatic COVID-19 digital biosignatures for rapid and accurate adult and child mass screening.
Detailed description
For the next few years or more, the planet probably won't have enough vaccine for everyone. Even as countries with large COVID-19 vaccination programs start pushing to resume travel and trade: We will not know who is vaccinated and who is not . We will not know who is an (a)symptomatic COVID-19 carrier and who is not. Because of this, the global community will remain in various stages of masking, social distancing, lock-down, and limited congregation because of cyclical COVID-19 spikes and people will continue to feel unsafe and afraid as novel COVID-19 variants appear and disappear. This large-scale, multi-site, multi-national study is informed by a completed pilot study at Johns Hopkins- NCT04556149. This study is designed to validate the ability of the imPulse™ Una infrasound-to-ultrasound e-stethoscope to rapidly and accurately screen outpatients with and without confirmed COVID-19 with sensitivity, specificity, positive and negative predictive value matching (PPA \>95%) for early, accurate, and rapid, self-directed and point-of-care diagnosis of COVID-19 in areas still lagging in access to vaccines.
Interventions
DEVICEimPulse™ Una infrasound-to-ultrasound e-stethoscope
The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
DIAGNOSTIC_TEST(PPA >95%) FDA EUA RT-PCR
Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
RADIATIONHR-CT-scan
High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
Sponsors
Asian Institute of Public Health
Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF)
Laboratoire de la foundation Gombes
Level 42 AI, Inc.
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Inclusion criteria
* Able to understand and willingness to comply with study procedures * Inpatient Cases - hospitalized patients with positive COVID-19 PCR test, collected from a respiratory sample within the last 7 days, AND pulmonary symptoms within 72 hours of enrollment * Outpatient Cases - participant being screened for COVID-19 with positive COVID-19 PCR test respiratory sample Controls - Outpatients with negative COVID-19 PCR test respiratory sample and no pulmonary diagnosis or symptoms Cases or Control not able to sit or stand will be allowed to participate in just the parts of the staircase exam they're capable of doing.
Exclusion criteria
* Assisted ventilation, including high flow nasal cannula, or ventilator support * Unable to comply with study procedures, defined at investigator's discretion * Participants with any visible skin infections or open wounds in areas where the imPulse™ Una device would be applied
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Digital vibroacoustic biomarker diagnostic performance characteristics | Enrollment through to study completion (min 48hrs through to 3 months) | Sensitivity, specificity, positive and negative predictive values - of the imPulse™ Una device for point-of-care diagnosis of COVID-19. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| imPulse™ Una infrasound-to-ultrasound e-stethoscope device safety | Enrollment through to study completion (min 48hrs through to 3 months) | Device safety |
Countries
Democratic Republic of the Congo, India, Senegal
Outcome results
None listed